Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire

利用缺乏内源性免疫球蛋白库的转基因“羊驼小鼠”生成纳米抗体

阅读:7
作者:Thomas Eden # ,Alessa Z Schaffrath # ,Janusz Wesolowski # ,Tobias Stähler ,Natalie Tode ,Nathalie Richter ,Waldemar Schäfer ,Julia Hambach ,Irm Hermans-Borgmeyer ,Jannis Woens ,Camille M Le Gall ,Sabrina Wendler ,Christian Linke-Winnebeck ,Martina Stobbe ,Iwona Budnicki ,Amelie Wanney ,Yannic Heitz ,Lena Schimmelpfennig ,Laura Schweitzer ,Dennis Zimmer ,Erik Stahl ,Fabienne Seyfried ,Anna J Gebhardt ,Lynn Dieckow ,Kristoffer Riecken ,Boris Fehse ,Peter Bannas ,Tim Magnus ,Martijn Verdoes ,Carl G Figdor ,Klaus F Hartlepp ,Hubertus Schleer ,Jonas Füner ,Nicola M Tomas ,Friedrich Haag ,Björn Rissiek ,Anna M Mann ,Stephan Menzel ,Friedrich Koch-Nolte

Abstract

Due to their exceptional solubility and stability, nanobodies have emerged as powerful building blocks for research tools and therapeutics. However, their generation in llamas is cumbersome and costly. Here, by inserting an engineered llama immunoglobulin heavy chain (IgH) locus into IgH-deficient mice, we generate a transgenic mouse line, which we refer to as 'LamaMouse'. We demonstrate that LamaMice solely express llama IgH molecules without association to Igκ or λ light chains. Immunization of LamaMice with AAV8, the receptor-binding domain of the SARS-CoV-2 spike protein, IgE, IgG2c, and CLEC9A enabled us to readily select respective target-specific nanobodies using classical hybridoma and phage display technologies, single B cell screening, and direct cloning of the nanobody-repertoire into a mammalian expression vector. Our work shows that the LamaMouse represents a flexible and broadly applicable platform for a facilitated selection of target-specific nanobodies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。